bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract A48: Sedentary behavior is associated with colorectal adenoma recurrence in men
Authors: Sardo Christine L. , Ashbeck Erin L. , Hibler Elizabeth A. , Roe Denise , Harris Robin B. , Cisneroz Martin , Lance Peter , Martinez Maria Elena , Thomson Cynthia A. , Thompson Patricia A. , Jacobs Elizabeth T. 
Published: May 2019

Abstract
The association between physical activity and colorectal adenoma is equivocal. This study was designed to assess the relationship between various physical activity types and colorectal adenoma recurrence in a pooled sample of participants from the Wheat Bran Fiber and Ursodeoxycholic Acid phase III clinical trials with available data from the baseline Arizona Activity Frequency Questionnaire and a follow-up colonoscopy (n=1,730). Logistic regression modeling was used to estimate the relationship between sedentary, recreational, and household activity on colorectal adenoma recurrence overall and stratified by gender. No statistically significant associations were found between any activity type and colorectal adenoma recurrence overall however, males with the highest sedentary time demonstrated a statistically significant 45% higher odds of adenoma recurrence. Compared to the lowest quartile of sedentary time, the ORs (95% CIs) for the second, third, and fourth quartiles among men were 1.31 (0.93, 1.84), 1.47 (1.04, 2.09) and 1.45 (1.02, 2.06) respectively (P trend=0.03). In males, those with low recreational activity and high sedentary time was also associated with greater risk for recurrent adenoma, with an OR (95% CI) of 1.41(1.00-2.00) for high sedentary time/low recreational activity compared to the reference group (low sedentary time/low recreational activity). Our results suggests that sedentary time is associated with a higher risk of colorectal adenoma recurrence among men, supporting a role for sedentary lifestyle in the early stages of carcinogenesis. Efforts to intervene on sedentary time should be evaluated as a method for reducing recurrent adenomas.
Citation Format: Christine L. Sardo, Erin L. Ashbeck, Elizabeth A. Hibler, Denise Roe, Robin B. Harris, Martin Cisneroz, Peter Lance, Maria Elena Martinez, Cynthia A. Thomson, Patricia A. Thompson, Elizabeth T. Jacobs. Sedentary behavior is associated with colorectal adenoma recurrence in men. [abstract]. In: Proceedings of the Twelfth Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2013 Oct 27-30; National Harbor, MD. Philadelphia (PA): AACR; Can Prev Res 2013;6(11 Suppl): Abstract nr A48.
Abstract A58: Serum transforming growth factor-β1 and risk of pancreatic cancer in three prospective cohort studies
Authors: Jacobs Eric J. , Newton Christina C. , Silverman Debra , Nogueira Leticia , Albanes Demetrius , Månnistö Satu , Stolzenberg-Solomon Rachael Z. 
Published: May 2019

Abstract
Background: Clinically evident chronic pancreatitis is an established, strong risk factor for pancreatic cancer. A small Japanese cohort study reported that pre-diagnostic serum transforming growth factor-β1 (TGF-β1) concentration, a potential marker of subclinical pancreatic inflammation, was associated with higher risk of pancreatic cancer.
Methods: Serum TGF-β1 concentrations were measured in pre-diagnostic samples drawn from 729 pancreatic cancer cases and 907 matched controls from a cohort of Finnish male smokers (the Alpha-Tocopherol, Beta-Carotene (ATBC) Cancer Prevention Study) and two cohorts of U.S. men and women, the Cancer Prevention Study-II (CPS-II) and the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Multivariable-adjusted odds ratios (ORs) were estimated using conditional logistic regression.
Results: Overall, high serum TGF-β1 concentration was associated with a marginally statistically significant increase in risk of pancreatic cancer (OR = 1.36, 95% confidence interval (CI), 0.98-1.88 for highest vs. lowest quintile). This association differed significantly by follow-up time (p = 0.02). Serum TGF-β1 concentration was not associated with risk during the first 10 years of follow-up, but was associated with risk during follow-up after 10 years (OR = 2.13, 95% CI 1.23-3.68 for highest vs. lowest quintile).
Conclusions: These results suggest that high serum TGF-β1 may be associated with increased risk of pancreatic cancer after a latency period of several years. Further research examining the magnitude and timing of associations between serum TGF-β1 and other potential markers of pancreatic inflammation may be useful in clarifying the role of inflammation in pancreatic carcinogenesis.
Citation Format: Eric J. Jacobs, Christina C. Newton, Debra Silverman, Leticia Nogueira, Demetrius Albanes, Satu Månnistö, Rachael Z. Stolzenberg-Solomon. Serum transforming growth factor-β1 and risk of pancreatic cancer in three prospective cohort studies. [abstract]. In: Proceedings of the Twelfth Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2013 Oct 27-30; National Harbor, MD. Philadelphia (PA): AACR; Can Prev Res 2013;6(11 Suppl): Abstract nr A58.
Abstract B59: Bilateral oophorectomy at age 55 or older does not reduce risk of breast cancer
Authors: Hofstatter Erin , Chagpar Anees 
Published: May 2019

Abstract
Introduction: It is widely accepted that premenopausal bilateral oophorectomy (BSO) reduces the risk of breast cancer. However, recently published data suggest that BSO done after menopause may also reduce risk of breast cancer. We sought to determine the impact of postmenopausal BSO on subsequent breast cancer diagnosis in a nationally representative sample.
Methods: The National Health Interview Survey (NHIS) is a population-based survey conducted annually by the CDC and is designed to be representative of the non-institutionalized civilian population in the United States. We utilized data from the 2010 NHIS cancer supplement to compare breast cancer diagnosis rates in women who underwent postmenopausal BSO versus those who did not. We defined our population of interest as those women ages 65 and older who underwent BSO between the ages of 55-64. Statistical analyses were conducted using SUDAAN software.
Results: In 2010, 21707 women ages 65 and older were surveyed, representing 190,813,389 people in the population. Of these, 0.97% underwent BSO between the ages of 55-64. 4.82% of women 65 years of age and older were surveyed reported developing breast cancer after the age of 65. On univariate analysis, 8.08% of women who had undergone a BSO between the ages of 55-64 developed breast cancer after age 65; whereas 24.11% of women who had not undergone a BSO developed breast cancer after age 65 (p=0.0188). The median age at which women undergoing BSO developed cancer was 74 years, on average 14 years after their oophorectomy. Having a BSO after menopause (vs. not having a BSO) was not associated with age of menarche 11 years or younger (13.8% vs. 15.6%, p=0.3701), parity (91.9% vs. 89.2%, p=0.3793), age at first live birth &lt; 20 (22.5% vs. 34.3%, p=0.0125), family history of a first degree relative with breast cancer (p=0.3726), body mass index 30 or above (31.6% vs. 28.2%, p=0.2811), income (p=0.2819), region (p=0.1811) or race/ethnicity (p=0.7611). However, BSO was found to be associated with higher education levels (p=0.0461), Medicare insurance (98.1% vs. 95.4%, p=0.0002) and increased ever use of HRT (50.3% vs. 25.6%, p= 0.0008). Controlling for these potential confounders on multivariate analysis, BSO was no longer associated with breast cancer after age 65 (OR = 0.38; 95% CI: 0.10-1.43, p=0.1522).
Conclusion: Bilateral oophorectomy performed in women after the age of 55 does not appear to reduce the risk of postmenopausal breast cancer. This patient population should continue to be counseled on other methods to reduce breast cancer risk, such as chemoprevention and weight loss.
Citation Format: Erin Hofstatter, Anees Chagpar. Bilateral oophorectomy at age 55 or older does not reduce risk of breast cancer. [abstract]. In: Proceedings of the Twelfth Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2013 Oct 27-30; National Harbor, MD. Philadelphia (PA): AACR; Can Prev Res 2013;6(11 Suppl): Abstract nr B59.
Abstract B61: Vitamin D-binding protein and pancreatic cancer: A nested case-control study
Authors: Piper Marina R. , Kopp William , Rager Helen , Horst Ronald L. , Stolzenberg-Solomon Rachael Z. 
Published: May 2019

Abstract
Research examining the association between vitamin D and pancreatic cancer is inconsistent, with some studies showing an elevated risk with increased vitamin D (Stolzenberg-Solomon, 2006, 2009, 2010) and another showing an inverse association. (Wolpin, 2012) This counterintuitive finding has led researchers to investigate levels of vitamin D-binding protein (DBP) as a possible explanation. DBP serves several important functions in the body, including acting as the primary carrier of vitamin D in the bloodstream. (Speeckaert, 2006) Previous research in the Alpha-Tocopherol, Beta-Carotene Study found an inverse trend for DBP and pancreatic cancer in male Finnish smokers, with higher compared to lower DBP concentrations showing a protective association with pancreatic cancer. (Weinstein, 2012)
We conducted a nested case-control study in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial cohort of men and women aged 55-74 at baseline. Between 1993 and 2010, 295 incident cases of pancreatic adenocarcinoma were reported (follow-up to 15.1 years). Two controls (n = 590) who were alive at the time the case was diagnosed were selected for each case and were matched by age, race, sex, month of blood draw. We calculated odds ratios (ORs) and 95% confidence intervals (CIs) using conditional logistic regression, adjusting for smoking status and diabetes mellitus.
DBP concentration was not significantly associated with pancreatic cancer overall (highest vs. lowest quintile, ≥7149.4 vs.&lt;3670.4 nmol/L: OR=1.75, 95% CI 0.91-3.37, p-trend=0.32). However, we observed a significantly elevated pancreatic cancer risk among cases diagnosed &gt;5 years after baseline (n = 214 cases, highest vs. lowest quintile, OR=2.12, 95% CI 1.01-4.43, p-value=0.047).
We did not confirm the protective association seen previously. Our results do not support the hypothesis that DBP plays a protective role in pancreatic cancer.
Funded by NCI Contract No. HHSN261200800001E.
Citation Format: Marina R. Piper, William Kopp, Helen Rager, Ronald L. Horst, Rachael Z. Stolzenberg-Solomon. Vitamin D-binding protein and pancreatic cancer: A nested case-control study. [abstract]. In: Proceedings of the Twelfth Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2013 Oct 27-30; National Harbor, MD. Philadelphia (PA): AACR; Can Prev Res 2013;6(11 Suppl): Abstract nr B61.
Abstract C01: Assessment of interest for breast cancer prevention trial participation among BRCA mutation carriers
Authors: Hurley Rachel M. , Suman Vera J. , Daly Mary , Olopade Funmi , Limburg Paul J. , Pruthi Sandhya 
Published: May 2019

Abstract
Purpose: BRCA1 and BRCA2 mutation carriers develop breast cancers with a tumor phenotype unique from spontaneous tumors. We surveyed documented BRCA mutation carriers to determine willingness to be contacted about participation in future breast cancer prevention research studies directed to their unique phenotype that may or may not require breast biopsies.
Methods: At each of the 3 participating institutions, women at least 20 years of age with a documented germline deleterious mutation in BRCA1 or BRCA2 and no prior history of breast cancer were contacted to participate in a survey to ascertain their willingness to be contacted to participate in future prevention trials. Survey results were summarized using descriptive statistics.
Results: Among 56 BRCA1 and BRCA2 mutation carriers who responded, 55.4% of women reported high or very high interest in participating in randomized control study of chemoprevention agent vs. placebo. Within this population, post-menopausal women demonstrated a higher interested in study participation (64.5%) versus pre-menopausal women (38.9%). When examining willingness to undergo breast biopsy for a chemoprevention study, women expressed near equal willingness (42.9%) and unwillingness (44.6%) for biopsy.
Conclusions: BRCA1 and BRCA2 mutation carriers demonstrated significant interest in breast cancer prevention study participation involving trial agent versus placebo, and an equal expression of willingness and unwillingness to undergo breast biopsy, establishing the feasibility for future research elucidating targeted chemoprevention agents.
Citation Format: Rachel M. Hurley, Vera J. Suman, Mary Daly, Funmi Olopade, Paul J. Limburg, Sandhya Pruthi. Assessment of interest for breast cancer prevention trial participation among BRCA mutation carriers. [abstract]. In: Proceedings of the Twelfth Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2013 Oct 27-30; National Harbor, MD. Philadelphia (PA): AACR; Can Prev Res 2013;6(11 Suppl): Abstract nr C01.
Abstract C09: Trends in colorectal cancer mortality and screening activities in European countries
Authors: Ouakrim Driss , Negri Eva , Malvezzi Matteo , Bleiberg Harry , Jenkins Mark , Boniol Mathieu , Autier Philippe 
Published: May 2019

Abstract
Background: Randomized trials have shown that fecal-occult-blood-test (FOBT) and endoscopic exterminations of the large bowel were able to decrease the risk of CRC death. We examined whether changes in CRC mortality in Europe were associated with a history of screening.
Methods: We used data collected as part of the Survey of Health, Aging, and Retirement in Europe (SHARE) project to extract information on exposure to CRC screening in subjects 50 years old or more living in 11 European countries. Distinct data were collected for endoscopy (colonoscopy or sigmoidoscopy) and FOBT. Using the WHO mortality database on causes of deaths, we fitted linear regressions from 1989 to 2010 and calculated changes in mortality for men and women living in each of the 11 countries. We used least square regression and computed R-square statistics (expressed in %) to provide estimates of the association between screening history and changes in CRC mortality.
Results: Over the 22-year period, changes in age-adjusted CRC mortality rates among males/females were -39/-47% in Austria, -34/-32% in France, -30/-44% in Germany, -26/-35% in Switzerland, -17/-23% in Italy, -14/-18% in Denmark, -10/-8% in Sweden, -4/-10% in the Netherlands, +29/-6% in Spain, and +30/+2% in Greece. In males, reports of ever having had an endoscopic examination of the large bowel ranged from 8% in Greece to 35% in Austria. For females, proportions of ever having undergone endoscopic examinations ranged from 8% in Greece to 36% in Austria. FOBT screening over the last 10 years, ranged from 4% in the Netherlands to 61% in Austria for both sexes. In males, a history of one or more endoscopic examination of the large bowel explained 73% of the decrease in CRC mortality. Having had at least one endoscopy or FOBT over the past 10 years explained 54 and 53% of the observed decrease in CRC mortality, respectively. In females, a history of one or more endoscopic examination of the large bowel explained 82% of the decrease in CRC mortality. Having had at least one endoscopy or FOBT over the past 10 years explained 89 and 72% of the decrease, respectively. All R-squares had an associated p value &lt; 0.001.
Conclusions: Changes in CRC mortality are correlated with the level of screening uptake. This provides “real world” evidence of the effectiveness of screening to prevent CRC mortality in the general population and a strong rational for current national CRC screening programs.
Citation Format: Driss Ouakrim, Eva Negri, Matteo Malvezzi, Harry Bleiberg, Mark Jenkins, Mathieu Boniol, Philippe Autier. Trends in colorectal cancer mortality and screening activities in European countries. [abstract]. In: Proceedings of the Twelfth Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2013 Oct 27-30; National Harbor, MD. Philadelphia (PA): AACR; Can Prev Res 2013;6(11 Suppl): Abstract nr C09.
Abstract C64: SNPs in genes of the glucose-metabolism pathway and prostate cancer: Interplay with metformin
Authors: Murtola Teemu J. , Wahlfors Tiina , Tammela Teuvo LJ , Mååttånen Liisa , Schleutker Johanna 
Published: May 2019

Abstract
Background: Energy metabolism is important for cancer progression. Energy-producing mitochondria also regulate cell growth and survival. Type II diabetes affects systemic energy metabolism, while both diabetes and antidiabetic treatment likely affect prostate cancer. We studied whether SNPs in genes of the energy-metabolism pathways associate with prostate cancer risk and prognosis, and whether the associations are modified by antidiabetic treatment.
Materials and methods: As part of an international PRACTICAL Consortium, 397 SNPs were genotyped on Illumina's custom array (iCOGS) among 3,719 participants of the Finnish Prostate Cancer Screening Trial and 1,528 hospital-based cases. The study population was linked to Finnish national prescription database for information on medication use.
After correction for multiple testing using adaptive permutation, SNPs showing an association with prostate cancer incidence or mortality at p &lt; 5 x 10-3 significance level were further explored in multivariable-adjusted Cox regression analyses. Analyses on prostate cancer risk and mortality were adjusted for age and screening trial arm. Analyses on prostate cancer case-fatality were additionally adjusted for tumor stage and grade at diagnosis.
Results: After permutation, a total of 30 and 10 SNPs were associated with prostate cancer risk or mortality, respectively. Of these, SNPs in genes PDK1, PGM1 and ENO1 showed consistent associations with prostate cancer risk, disease grade/stage and prostate cancer mortality/case fatality in both study cohorts.
The associations with prostate cancer were stronger among antidiabetic drug users in general, although the interaction terms were not significant. Higher cumulative amount of metformin use attenuated the risk increase among antidiabetic drug users.
Conclusions: Polymorphisms in genes of the energy-metabolism pathways associate with prostate cancer risk, disease severity and prognosis. This association may be modified by diabetes and antidiabetic drug usage. If validated in further studies, these polymorphisms could be used in risk stratification of prostate cancer patients.
Citation Format: Teemu J. Murtola, Tiina Wahlfors, Teuvo LJ Tammela, Liisa Mååttånen, Johanna Schleutker. SNPs in genes of the glucose-metabolism pathway and prostate cancer: Interplay with metformin. [abstract]. In: Proceedings of the Twelfth Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2013 Oct 27-30; National Harbor, MD. Philadelphia (PA): AACR; Can Prev Res 2013;6(11 Suppl): Abstract nr C64.
Abstract CN02-02: Elucidating mechanisms of environmentally induced kidney cancers
Authors: Threadgill David 
Published: May 2019

Abstract
Epidemiology data suggests that exposure to trichloroethylene (TCE) is associated with increased susceptibility to a variety of diseases including elevated incidence of kidney cancer. Molecular analysis of kidney cancers from workers in Germany revealed a TCE-specific hotspot mutation in the von Hippel-Lindau (VHL) gene. We used a mouse embryonic stem cell assay to demonstrate that the TCE-associated VHL mutation is highly transforming and confers apoptotic and DNA damage resistance. To investigate genetic susceptibility to TCE, we exposed a genetically diverse mouse population to TCE with or without inorganic arsenic (iAS), a toxicant naturally found in the environment in many locations. We observed cooperation between TCE and iAS in the induction of a gene expression signature in kidneys identical to that caused by the TCE-associated VHL mutation. After one year of exposure, subsets of mice developed kidney cancers, some of which became metastatic to the lung. A systems analysis revealed complex patterns of genetic susceptibility. The results demonstrate that chemical combinations can elicit additive and synergistic toxicities in genetically susceptible individuals.
Citation Format: David Threadgill. Elucidating mechanisms of environmentally induced kidney cancers. [abstract]. In: Proceedings of the Twelfth Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2013 Oct 27-30; National Harbor, MD. Philadelphia (PA): AACR; Can Prev Res 2013;6(11 Suppl): Abstract nr CN02-02.
Abstract CN03-01: The role of NCI's Cancer Intervention and Surveillance Modeling Network (CISNET) in guiding cancer control planning and priorities
Authors: Feuer Eric J. 
Published: May 2019

Abstract
CISNET is a consortium of NCI-sponsored investigators that use simulation modeling to understand past trends in cancer incidence and mortality, and to guide public health research and priorities. In this talk we describe the role of simulation modeling in understanding the population impact of interventions (i.e. screening, treatment and prevention). We review some of the unique aspects of modeling as carried out by CISNET, i.e. the development of flexible broad-based disease models, the ability to model multiple birth cohorts, comparative modeling, transparency in model structure and assumptions, and outreach to partners to make the modeling relevant. Finally, we summarize some of the major accomplishments of CISNET.
Citation Format: Eric J. Feuer. The role of NCI's Cancer Intervention and Surveillance Modeling Network (CISNET) in guiding cancer control planning and priorities. [abstract]. In: Proceedings of the Twelfth Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2013 Oct 27-30; National Harbor, MD. Philadelphia (PA): AACR; Can Prev Res 2013;6(11 Suppl): Abstract nr CN03-01.
Abstract CN03-02: Modeling past and future smoking patterns in the U.S
Authors: Holford Theodore R. 
Published: May 2019

Abstract
To evaluate the impact of tobacco control interventions on smoking-related mortality it is essential to develop smoking histories over the life course of different birth cohorts. Analyses that extend the detail beyond prevalence in order to also include initiation, cessation and intensity has received limited attention. US National Health Interview Surveys conducted from 1965-2009 provided cross-sectional information on current smoking behavior. Some of these surveys also provided additional detail on age at initiation and cessation, and smoking intensity. Age-period-cohort models with constrained natural splines were adjusted for survival differences by smoking status to obtain estimates of the prevalence of current, former and never smokers for ages 35-99 in cohorts beginning in 1890. This approach also yielded yearly estimates of initiation, cessation and smoking intensity for each birth cohort which were projected forward through 2050 based on recent trends. These summaries show clear trends by gender, cohort and age over time. If current patterns persist, a slow decline in smoking prevalence is projected from 2010 through 2040. This new method of generating smoking histories has been included in the National Cancer Institute's Smoking History Generator which can be used in micro-simulation models to assess the impact of alternative tobacco control strategies.
Citation Format: Theodore R. Holford. Modeling past and future smoking patterns in the U.S. [abstract]. In: Proceedings of the Twelfth Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2013 Oct 27-30; National Harbor, MD. Philadelphia (PA): AACR; Can Prev Res 2013;6(11 Suppl): Abstract nr CN03-02.